ARK Genomic Revolution ETF vs Asana Inc. — how do they compare? ARK Genomic Revolution ETF trades at $40.55, while Asana Inc. trades at $7.3 (market cap $1.69B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Asana Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | ASAN | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $15.35 |
52-Week Low | $23.09 | $5.46 |
Market Cap | — | $1.69B |
Enterprise Value | — | $1.51B |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
No Aura AI signal available yet.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →